雷洛昔芬
骨质疏松症
医学
绝经后骨质疏松症
重症监护医学
临床试验
绝经后妇女
替代医学
骨矿物
内科学
病理
三苯氧胺
癌症
乳腺癌
作者
Jozef Rovenský,Juraj Payer
标识
DOI:10.1007/978-3-211-79280-3_924
摘要
Several years ago, Osteoporosis Australia published Guidelines for the management of osteoporosis. Since then significant advances in our understanding of the treatment of osteoporosis have been published. The importance of this is heightened as early diagnosis is now possible with precise methods of bone density measurement.This article presents updated guidelines developed on behalf of Osteoporosis Australia for the treatment of postmenopausal osteoporosis to help general practitioners identify those women at risk and to review current treatment strategies.Osteoporosis and its associated problems are major health concerns in Australia, especially with an ageing population. While important principles of management are still considered to be maximising peak bone mass and prevention of postmenopausal bone loss by oestrogen therapy, new clinical trial data about drugs such as raloxifene and the bisphosphonates have recently become available and the relative role of various agents is gradually becoming clearer.
科研通智能强力驱动
Strongly Powered by AbleSci AI